Retatrutide Cost: No Price Yet, and My Estimate Is $450 to $650 a Month
I paid Lilly’s self-pay price for Zepbound for months, and retatrutide has no announced price yet, so here is what Lilly’s own price ladders imply.
GLP-1, Preventive Health
GLP-1, Preventive Health
Does CagriSema Have a Brand Name Yet?
CagriSema has no announced brand name as of September 4, 2026. Novo Nordisk owns eleven invented names it could use, and it bought the matching web address for only six of them.
GLP-1, Healthcare
Is CagriSema Covered by Medicare? Not Yet, and Here Is What Would Change That
CagriSema is not approved, so Medicare does not cover it. Here are the three routes after the FDA decides: the $50 Medicare GLP-1 Bridge, regular Part D, or the CagriSema cost without insurance.
GLP-1, Healthcare
CagriSema vs Zepbound: The New Combo Couldn’t Prove It Matches the Drug I’m On
Novo’s own head-to-head could not show CagriSema was as good as tirzepatide. I take Zepbound myself, and I go through both sets of numbers, plus the brand names Novo has filed, including Wegovamy.
GLP-1, Preventive Health
Does Retatrutide Have a Brand Name Yet?
Retatrutide still has no brand name. But Lilly filed 20 new trademarks in a month and 19 are built on reta, from VYNRETA to YEZRETA. Here is the whole list, which domains Lilly quietly bought first, and what happened the last time it did this.
GLP-1, Preventive Health
Retatrutide vs Zepbound: Is Lilly’s Next Weight-Loss Shot Worth Waiting For?
Retatrutide beat Zepbound’s numbers in its own trials, and it did not need its top dose to do it. I take Zepbound, I lost about 170 pounds on it, and I am staying put.
Medicine 3.0, Preventive Health
A Zero Calcium Score Isn’t the Whole Story. But the $2,000 Scan Isn’t Either.
My coronary calcium score is zero. What a zero doesn’t rule out, what a new NEJM study found about plaque without calcium, and whether the $2,000 AI heart scan (Cleerly or HeartFlow) is worth it at 53.
Cholesterol, Heart & Bloodwork, Medicine 3.0, Preventive Health
Heart Attacks Were 43% Lower With a Statin in Adults Over 70. Cardiovascular Deaths Were Not.
I do not take a statin. I got my ApoB to 59 with about 170 pounds of weight loss and a generic ezetimibe that runs me twenty dollars a month, so when a big statin trial reads out I have nothing invested in the answer. I have also written here about why most of the
GLP-1, Heart & Bloodwork
Mounjaro Just Got a Heart Indication. The Trial Behind It Didn’t Beat the Older Drug.
Updated September 16, 2026 with the revised label now posted to DailyMed. The FDA approved Mounjaro today to lower the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes who are at high risk for those events. That is a real expansion, and for a lot of people it is
Medicine 3.0, Peptides
BPC-157 Human Trials: 5 Studies, ~80 People, One Failed RCT
Not one of them tested an injury. I pulled every record in FDA’s July 2026 review and the registries behind it.